千红制药(002550) - 2022 Q1 - 季度财报

Revenue and Profitability - Revenue for Q1 2022 reached ¥552,220,533.56, an increase of 41.16% compared to ¥391,207,729.22 in the same period last year[3] - Net profit attributable to shareholders was ¥128,247,521.34, up 135.93% from ¥54,359,079.83 year-on-year[3] - Basic earnings per share increased to ¥0.1026, reflecting a growth of 135.32% compared to ¥0.0436 in the same quarter last year[3] - Total operating revenue for the current period reached ¥552,220,533.56, a significant increase of 41.2% compared to ¥391,207,729.22 in the previous period[24] - Net profit for the current period was ¥125,796,128.32, representing a substantial increase of 131.1% compared to ¥54,460,883.29 in the same period last year[27] - Earnings per share (EPS) for the current period was reported at ¥0.1026, compared to ¥0.0436 in the previous period, reflecting a growth of 134.6%[30] Cash Flow and Financial Stability - Operating cash flow for the quarter was ¥91,973,048.64, a significant improvement of 195.97% from a negative cash flow of -¥95,833,609.11 in the previous year[3] - Cash flow from operating activities generated ¥91,973,048.64, a turnaround from a negative cash flow of -¥95,833,609.11 in the previous period[31] - Cash and cash equivalents increased by 32.6% due to improved collection of receivables during the reporting period[6] - The net increase in cash and cash equivalents was $201,373,915.96, contrasting with a decrease of $50,535,938.16 in the previous period[33] - The ending balance of cash and cash equivalents stood at $819,179,841.19, up from $465,212,988.18[33] Assets and Liabilities - Total assets at the end of the quarter were ¥2,698,419,871.81, representing a 7.58% increase from ¥2,508,397,996.17 at the end of the previous year[3] - The company's total liabilities increased to RMB 453,810,999.97 from RMB 390,237,603.01, marking an increase of about 16.25%[21] - Current assets rose to RMB 1,711,362,259.14, up from RMB 1,569,941,638.14, indicating an increase of about 8.99%[18] - The company's accounts receivable increased to RMB 419,726,427.58 from RMB 395,723,389.25, reflecting a growth of about 6.06%[15] - The total equity attributable to the parent company rose to RMB 2,256,150,351.03 from RMB 2,127,250,479.33, showing an increase of approximately 6.06%[21] Operating Performance - Operating income growth was driven by increased sales, with operating costs rising by 51.55% in line with revenue growth[6] - Total operating costs amounted to ¥451,115,340.28, up 41.6% from ¥318,396,525.67 in the prior period, with operating costs specifically rising from ¥216,882,527.24 to ¥328,680,881.81[24] - The company reported a total profit of ¥151,803,912.40, which is more than double the ¥68,693,321.89 recorded in the prior period, indicating strong operational performance[27] Other Financial Metrics - Non-recurring gains and losses totaled ¥51,864,824.32, primarily due to asset disposal gains and government subsidies[5] - The company’s tax expenses increased to ¥26,007,784.08 from ¥14,232,438.60, marking an increase of 82.5%[27] - Other comprehensive income after tax for the current period was ¥652,350.36, significantly higher than ¥27,571.26 in the previous period[27] - Investment income improved to a loss of -¥1,018,242.78 from a larger loss of -¥6,546,517.79, showing a positive trend in investment performance[24] Borrowings and Inventory - Short-term borrowings grew by 114.05%, attributed to increased working capital loans for production operations[6] - Inventory decreased to RMB 321,397,381.16 from RMB 400,630,285.02, representing a decline of about 19.73%[18] - Short-term borrowings increased significantly to RMB 191,490,038.61 from RMB 89,461,823.36, indicating a rise of approximately 113.48%[21] - The company reported a decrease in employee compensation payable to RMB 27,276,227.70 from RMB 47,034,847.33, a reduction of approximately 42.03%[21]